03.04.2024 • News

Sika Acquires Concrete Refurbishment Company in the US

Swiss construction chemicals major Sika has acquired Kwik Bond Polymers (KBP), a US-based manufacturer of polymer systems for the refurbishment of concrete infrastructure. Financial details of the transaction were not disclosed.

KBP has production facilities at its headquarters in Benicia, California, and additional production and warehousing near Pittsburgh, Pennsylvania. Its portfolio includes polymer technologies for long-lasting protection of bridge decks and other concrete infrastructure applications.

According to Sika, KBP’s solutions contribute to an overall carbon footprint reduction in the construction industry by increasing the lifespan of construction projects.

Infrastructure in the USA is facing unprecedented challenges due to lack of maintenance and under-investment over many years, Sika commented in a statement. In 2022, a $1.2 trillion infrastructure bill was approved that will support decade-long funding for critical infrastructure upgrades.

Mike Campion, Sika’s regional manager Americas, said: "Kwik Bond is a perfect complement to Sika’s current infrastructure focus and product portfolio. By preserving and extending the service-life of our concrete infrastructure, we deliver outstanding customer value and significant sustainability benefits to the construction industry."

© Victor Maffe/iStockphoto
© Victor Maffe/iStockphoto

Company

Logo:

Sika AG

Zugerstrasse 50
CH-6340 Baar (ZG)
Switzerland

Company contact







Article

The State of the US Specialty Chemicals Industry
Reshaping Specialty Chemicals Manufacturing

The State of the US Specialty Chemicals Industry

SOCMA's Jenn Klein examines how specialty chemical manufacturers — the invisible backbone behind pharmaceuticals, electronics, agriculture, and energy — are navigating supply chain shifts, policy uncertainty, and constant change while remaining resilient, disciplined, and focused on execution.

Expert Insights

ADCs for Precision Cancer Therapy
Comprehensive Insights into Antibody–Drug Conjugates

ADCs for Precision Cancer Therapy

Explore how antibody-drug conjugates are reshaping precision cancer therapy and discover what it takes to successfully develop, manufacture, and scale these complex biologics.

most read